As fellow pet people, we at Zoetis know the joy and meaning that pets bring to our homes. They are a part of our families, and they deserve the highest quality care when they are ill. That’s why we’re committed to creating safe and effective products like Librela, which has helped millions of dogs suffering from osteoarthritis pain to remain happy and healthy.

Latest Librela News

Common Pet Parent Questions

Ask Questions About Our Products

Please refer to the full Prescribing Information for approved product labeling and Important Safety Information.

Contact our Zoetis Veterinary Medical Information Product Support (VMIPS) at 1‑888‑963‑8471

You may also contact our veterinary team using this form:

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.

  1. Global pharmacovigilance data on file.
  2. Michels GM, Honsberger NA, Walters RR, Tena JKS, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Veterinary Anaesthesia and Analgesia 2023; 50(5): 446-458. (
  3. Corral MJ, Moyaert H, Fernandes T, Escalada M, Kira S Tena J, Walters RR, Stegemann MR. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia 2021;48(6):943-955. (doi: 10.1016/j.vaa.2021.08.001).
  4. Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631-637. doi:10.2460/ajvr.68.6.631
  5. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. doi:10.2460/ javma.233.8.1278
  6. Reid J, Bartram D, Thompson J, Scales-Theobald E, Gildea E. Measuring improvement in quality of life of dogs with osteoarthritis (OA) treated with bedinvetmab (Librela®) using an app-based, validated, owner-reported, health-related quality of life (HRQL) outcome measure (VetMetrica™). Frontiers in Veterinary Science 2024 (under review)
  7. Anderson KL, Zulch H, O’Neill DG, Meeson RL, Collins LM. Risk factors for canine osteoarthritis and its predisposing arthropathies: a systematic review. Front Vet Sci. 2020;7:200. doi:10.3389/fvets.2020.00220
  8. IHS Markit. (2021) Canine and Feline Pain Market 2021: Animal Health Market Analysis; Wright A, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract, 2022.
  9. PetTrak US Pain Factored National January 2023.
  10. Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016/j. tvjl.2019.07.001.
  11. Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.
  12. Librela Vet Pulse W3, March 2023, Forward Group
  13. BIO’SAT Vet Market Research, Study Report Librela UK, November 2021
  14. Data on File. Zoetis Inc. March 2024
  15. Council for International Organizations of Medical Sciences (CIOMS): Pharmacovigilance. accessed May 21 2024.